amylin glp-1 dual agonist Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity Amylin Commands Weight Loss Attention
Description
Larger molecules face increasing resistance
The effect of semaglutide subcutaneous injection at 2.4 mg per week in patients with HFpEF and obesity (BMI 30 kg/m 2 ) but without diabetes was tested in STEP-HFpEF [29]
Set realistic goals: Help patients set achievable weight loss and fitness goals that they can maintain in the long run
Ann Intern Med 1999
Comparing these two classes of medications is important with respect to perioperative patients requiring glycemic control
